The Post-Aromatase Battlefield: Breaking Down Eli Lilly's Inluriyo Strategy, Companion Diagnostic Moats, and the Oral SERD Market Shift
Dr. Dereck Mush, MD, MBA
Guardant Health
Liquid biopsy company whose Guardant360 CDx panel is the companion diagnostic for Lilly's Inluriyo combination.
What they do
Guardant Health offers non-invasive liquid biopsy tests that detect cancer from tumor DNA in blood samples. Oncology clinics and biopharmaceutical partners use these diagnostics to guide treatment decisions, monitor recurrence, and accelerate clinical trials for advanced-stage cancer patients.
The record
- Vertical
- Oncology
- Sub-segment
- Early cancer detection
- Product type
- Diagnostics
- Stage
- Public
- Headquarters
- Redwood City, United States
- Region
- North America
- Founded
- 2012
- Total funding
- $550M raised
Notable investors: SoftBank Vision Fund, Sequoia Capital, Khosla Ventures, Lightspeed Venture Partners.
Also in Oncology
Related on The Signal
Dr. Dereck Mush, MD, MBA
PATHFINDER 2 Results: What the Galleri Multi-Cancer Blood Test Actually Found
Dr. Dereck Mush, MD, MBA
The Curative Adjuvant Checkpoint Pivot: How Genentech's ATOMIC Approval Redefines Early GI Oncology Economics and Reflex Testing Infrastructure
Dr. Dereck Mush, MD, MBA
The MCED Inflection Point: What Galleri's FDA Panel Backing Means for Cancer Screening
Dr. Dereck Mush, MD, MBA